Combined ARHGEF6 and Tumor Mutational Burden may serve as a potential biomarker for immunotherapy of lung adenocarcinoma
Li Tong,
Sichu Wang,
Juanjuan Yang,
Qing Zhang,
Xue Gu,
Taoming Mo,
Yang Luo,
Chenqian Zhang,
Jianguo Zhang,
Yifei Liu
Affiliations
Li Tong
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Dalian Medical University, Dalian, China
Sichu Wang
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Dalian Medical University, Dalian, China
Juanjuan Yang
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China
Qing Zhang
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China
Xue Gu
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Medical School of Nantong University, Nantong, China
Taoming Mo
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Medical School of Nantong University, Nantong, China
Yang Luo
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Medical School of Nantong University, Nantong, China
Chenqian Zhang
Medical School of Nantong University, Nantong, China
Jianguo Zhang
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China
Yifei Liu
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China; Medical School of Nantong University, Nantong, China; Corresponding author. Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China.
ARHGEF6, a member of the Dbl-related guanylate exchanger (GEF) family, is highly expressed in gastric cancer and glioma. However, scientists still do not know whether it plays a pivotal role in the pathogenesis of lung adenocarcinoma（LUAD）. The prognostic significance of ARHGEF6 expression was assessed by TCGA data. This paper focuses on the level of immune infiltration associated with ARHGEF6 and explored the relationship of this gene with the tumor mutational burden (TMB), immune checkpoints, and drug sensitivity. The results showed that the high expression of ARHGEF6 was associated with a good prognosis in LUAD patients, and positively correlated with a variety of immune cells and drugs. Meanwhile, ARHGEF6 was found to be negatively correlated with TMB. In conclusion, the results of this study suggest that ARHGEF6 is a protective gene in LUAD patients. A combination of ARHGEF6 and TMB could be used as a potential biomarker in the screening of immunotherapy regimens, which are provided to patients with LUAD.
